Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Dynamics of T cell responses to COVID-19 vaccines and breakthrough infection in people living with HIV receiving antiretroviral therapy

Sneha Datwani, Rebecca Kalikawe, Rachel Waterworth, Francis M. Mwimanzi, Richard Liang, Yurou Sang, View ORCID ProfileHope R. Lapointe, Peter K. Cheung, F. Harrison Omondi, Maggie C. Duncan, Evan Barad, Sarah Speckmaier, Nadia Moran-Garcia, Mari L. DeMarco, Malcolm Hedgcock, Cecilia T. Costiniuk, Mark Hull, Marianne Harris, Marc G. Romney, Julio S.G. Montaner, Zabrina L. Brumme, View ORCID ProfileMark A. Brockman
doi: https://doi.org/10.1101/2024.03.08.24304006
Sneha Datwani
1Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Kalikawe
1Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Waterworth
1Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
3Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francis M. Mwimanzi
1Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Liang
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yurou Sang
1Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hope R. Lapointe
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hope R. Lapointe
Peter K. Cheung
1Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Harrison Omondi
1Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maggie C. Duncan
1Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evan Barad
1Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Speckmaier
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadia Moran-Garcia
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mari L. DeMarco
4Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada;
5Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malcolm Hedgcock
6Spectrum Health, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cecilia T. Costiniuk
7Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre and Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Hull
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
8Department of Medicine, University of British Columbia, Vancouver, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianne Harris
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
9Department of Family Practice, Faculty of Medicine, University of British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc G. Romney
4Department of Pathology and Laboratory Medicine, Providence Health Care, Vancouver, Canada;
5Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julio S.G. Montaner
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
8Department of Medicine, University of British Columbia, Vancouver, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zabrina L. Brumme
1Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mark_brockman{at}sfu.ca zbrumme{at}sfu.ca
Mark A. Brockman
1Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;
2British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
3Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark A. Brockman
  • For correspondence: mark_brockman{at}sfu.ca zbrumme{at}sfu.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Introduction People living with HIV (PLWH) can exhibit impaired immune responses to vaccines. Accumulating evidence indicates that PLWH, particularly those receiving antiretroviral therapy, mount strong antibody responses to COVID-19 vaccination, but fewer studies have examined cellular immune responses to vaccination. We measured SARS-CoV-2 spike-specific CD4+ and CD8+ T cell responses generated by two and three doses of COVID-19 vaccine in PLWH receiving antiretroviral therapy, compared to control participants without HIV. We also quantified T cell responses after post-vaccine breakthrough infection, and receipt of fourth vaccine doses, in a subset of PLWH.

Methods We quantified CD4+ and CD8+ T cells reactive to overlapping peptides spanning the ancestral SARS-CoV-2 spike protein in 50 PLWH and 87 controls without HIV, using an activation induced marker (AIM) assay. All participants remained SARS-CoV-2 naïve until at least one month after their third vaccine dose. SARS-CoV-2 infection was determined by seroconversion to nucleocapsid (N) antigen, which occurred in 21 PLWH and 38 controls post-third dose. Multivariable regression analyses were used to investigate relationships between sociodemographic, health and vaccine-related variables and vaccine-induced T cell responses, as well as breakthrough infection risk.

Results A third vaccine dose boosted spike-specific CD4+ and CD8+ T cell frequencies significantly above those measured after the second dose (all p<0.0001). Median T cell frequencies did not differ between PLWH and controls after the second dose (p>0.1), but CD8+ T cell responses were modestly lower in PLWH after the third dose (p=0.02), an observation that remained significant after adjustment for sociodemographic, health and vaccine-related variables (p=0.045). In PLWH who experienced breakthrough infection, median T cell frequencies increased even higher than those observed after three vaccine doses (p<0.03), and CD8+ T cell responses in this group remained higher even after a fourth vaccine dose (p=0.03). In multivariable analysis, the only factor associated with increased breakthrough infection risk was younger age, consistent with the rapid increases in SARS-CoV-2 seropositivity among younger adults in Canada after the initial appearance of the Omicron variant.

Conclusion PLWH receiving antiretroviral therapy mount strong T cell responses to COVID-19 vaccines that can be enhanced by booster doses or breakthrough infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the Public Health Agency of Canada through a COVID-19 Immunology Task Force COVID-19 Hot Spots Award (2020-HQ-000120 to MGR, ZLB, MAB). Additional funding was received from the Canadian Institutes for Health Research (GA2-177713 to MAB), the Coronavirus Variants Rapid Response Network (FRN-175622 to MAB), the Canada Foundation for Innovation through Exceptional Opportunities Fund COVID-19 awards (to MAB, MLD, ZLB). FMM was supported by fellowships from the Canadian Institutes of Health Research (CIHR) Canadian HIV Trials Network and Michael Smith Health Research BC (MSHR-BC). FHO was supported by a Ph.D. fellowship from the Sub-Saharan African Network for TB-HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant DEL-15-006). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant 107752/Z/15/Z] and the UK government. MCD was supported by a CIHR CGS-M award. MLD and ZLB hold Scholar Awards from MSHR-BC.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Written informed consent was obtained from all participants. This study was approved by the University of British Columbia/Providence Health Care and Simon Fraser University Research Ethics Boards.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

The datasets analysed in this study are available from the corresponding author upon reasonable request. Data have also been deposited into the COVID-19 Immunology Task Force (CITF) data bank, available online at: https://portal.citf.mcgill.ca.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 11, 2024.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Dynamics of T cell responses to COVID-19 vaccines and breakthrough infection in people living with HIV receiving antiretroviral therapy
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Dynamics of T cell responses to COVID-19 vaccines and breakthrough infection in people living with HIV receiving antiretroviral therapy
Sneha Datwani, Rebecca Kalikawe, Rachel Waterworth, Francis M. Mwimanzi, Richard Liang, Yurou Sang, Hope R. Lapointe, Peter K. Cheung, F. Harrison Omondi, Maggie C. Duncan, Evan Barad, Sarah Speckmaier, Nadia Moran-Garcia, Mari L. DeMarco, Malcolm Hedgcock, Cecilia T. Costiniuk, Mark Hull, Marianne Harris, Marc G. Romney, Julio S.G. Montaner, Zabrina L. Brumme, Mark A. Brockman
medRxiv 2024.03.08.24304006; doi: https://doi.org/10.1101/2024.03.08.24304006
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Dynamics of T cell responses to COVID-19 vaccines and breakthrough infection in people living with HIV receiving antiretroviral therapy
Sneha Datwani, Rebecca Kalikawe, Rachel Waterworth, Francis M. Mwimanzi, Richard Liang, Yurou Sang, Hope R. Lapointe, Peter K. Cheung, F. Harrison Omondi, Maggie C. Duncan, Evan Barad, Sarah Speckmaier, Nadia Moran-Garcia, Mari L. DeMarco, Malcolm Hedgcock, Cecilia T. Costiniuk, Mark Hull, Marianne Harris, Marc G. Romney, Julio S.G. Montaner, Zabrina L. Brumme, Mark A. Brockman
medRxiv 2024.03.08.24304006; doi: https://doi.org/10.1101/2024.03.08.24304006

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (755)
  • Anesthesia (221)
  • Cardiovascular Medicine (3288)
  • Dentistry and Oral Medicine (364)
  • Dermatology (277)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1169)
  • Epidemiology (13359)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5147)
  • Geriatric Medicine (481)
  • Health Economics (782)
  • Health Informatics (3264)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (429)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14622)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (127)
  • Nephrology (522)
  • Neurology (4919)
  • Nursing (262)
  • Nutrition (727)
  • Obstetrics and Gynecology (882)
  • Occupational and Environmental Health (795)
  • Oncology (2519)
  • Ophthalmology (723)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (556)
  • Psychiatry and Clinical Psychology (4205)
  • Public and Global Health (7499)
  • Radiology and Imaging (1704)
  • Rehabilitation Medicine and Physical Therapy (1011)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (205)